Sedation as a Placement Strategy: How States Drug Foster Children Into Compliance While a 2011 Federal Law Goes Unaudited

For fifteen years, federal law has required every state to file protocols for "the appropriate use and monitoring of psychotropic medication" as a condition of receiving Title IV-B child welfare funds. Every state files something. Almost no one checks whether the document describes anything that actually happens. In the interval, children in foster care have been prescribed psychotropic drugs at two to five times the rate of other children on Medicaid — including infants and toddlers for whom no psychiatric indication exists — with federal inspectors finding quality-of-care problems in two-thirds of the antipsychotic claims they sampled and one in three medicated foster children receiving no treatment planning or monitoring their own state required. Four federal class actions covering more than 18,000 children in government custody have now alleged the same structural failure in four different jurisdictions, and courts have credited it in every one. The pattern that emerges is not a medical error rate. It is a staffing model.

How the Mechanism Actually Works

A child enters foster care carrying trauma. As much as 80 percent of the foster population enters with significant mental health needs, the HHS Office of Inspector General found in its 2018 review. What that child needs — a stable placement, a consistent adult, trauma-informed therapy — is expensive, slow, and in chronic short supply. What is instantly available, reimbursable, and requires no additional staff is a prescription.

The consent architecture is where the system breaks. In a family, a parent who knows the child signs for the medication. In foster care, the signature migrates. Depending on the state, it may go to a caseworker managing 20 other children, an agency medical director who has never met the child, a residential facility administrator, a guardianship office processing thousands of requests a year, or — in states like Florida and California, which are the exception rather than the rule — a judge. Nobody in that chain has the two things informed consent requires: knowledge of the child, and no stake in the outcome. The people with the strongest incentive to sedate are frequently the people asked to approve it.

The Imprint's 2025 fifty-state review, published jointly with MindSite News under the title "All I Did Was Sleep," found the gap is not subtle: thirteen state child welfare agencies could not produce a psychotropic medication policy at all. Agencies in Massachusetts, North Dakota, Arkansas, West Virginia, Kansas, Alabama, and Kentucky confirmed or did not dispute that they have no child-welfare policy specific to psychotropics — fourteen years after Congress required one.

The Numbers, and the Database That Doesn't Exist

The foundational federal finding is GAO-12-201, issued in December 2011. Examining Medicaid claims in Florida, Massachusetts, Michigan, Oregon, and Texas, GAO found foster children were prescribed psychotropic medications at rates 2.7 to 4.5 times those of non-foster children on Medicaid. The age breakdown is the part that should have ended the practice: among children under one year old, 0.3 to 2.1 percent of foster infants received a psychotropic drug, versus 0.1 to 1.2 percent of non-foster infants. GAO's own expert panel stated flatly that there are no established mental health indications for psychotropic drugs in infants.

Polypharmacy tracked the same way. Concurrent use of five or more psychotropic medications ranged from 0.13 to 1.33 percent among foster children, against 0.01 to 0.07 percent among non-foster children — a gap of up to two orders of magnitude. Roughly 13 percent of medicated foster children were on three or more at once.

A 2023 Baylor College of Medicine analysis of 397,340 Medicaid-enrolled children ages 1 to 18 found 35 percent of foster children prescribed psychotropics versus 8 percent of non-foster children. Antipsychotic utilization runs 2 to 3 percent among children generally and 10 to 15 percent among foster children.

Then the trail goes cold — by design. There is no national registry of how many foster children are on how many psychotropic drugs, at what doses, for how long. The 2016 AFCARS final rule would have partially fixed this by adding health-care tracking data elements to the federal foster care reporting system. The 2020 revision eliminated those elements, along with ICWA and LGBTQ+ data. States report their protocols narratively, in Annual Progress and Services Reports, first required for FY2013. A narrative is not a number. The Children's Bureau reviews the narrative.

The Money

Medicaid is the payer, and the sums are not marginal. Medicaid spent more than $3.6 billion on second-generation antipsychotics in 2011 alone, with five branded drugs — aripiprazole, quetiapine, olanzapine, ziprasidone, and paliperidone — accounting for $3.3 billion, or 90 percent, of that. Texas Medicaid spent $96 million on antipsychotics for children and teenagers in a single year, a figure that included three infants dosed before their first birthdays.

The deeper economics sit in residential care. The Senate Finance Committee's June 12, 2024 report, Warehouses of Neglect: How Taxpayers Are Funding Systemic Abuse in Youth Residential Treatment Facilities, examined four operators — Universal Health Services, Acadia Healthcare, Devereux Advanced Behavioral Health, and Vivant Behavioral Healthcare (formerly Sequel) — and found facilities billing taxpayers or parents as much as $1,200 per child per day while leaving children under-supervised and untreated. The National Disability Rights Network's Desperation Without Dignity documented medication administered as chemical restraint "for staff convenience," including an Arkansas facility where staff "routinely simultaneously chemically restrained and secluded children."

The arithmetic is straightforward. A facility billing $1,200 a day that cannot recruit and retain qualified staff has two ways to keep a unit safe enough to stay licensed: hire more people, or lower the children's activity level. One of those costs money. The other is reimbursed.

Federal money flows to these operators from more than one direction. A search of federal award records for Devereux — one of the four operators named by Senate Finance — returns more than $91.7 million in federal grants, including $48.2 million from HHS under CFDA 93.566 in FY2022 and $30.4 million under CFDA 93.676, the Unaccompanied Children program, in FY2019, with further 93.676 awards continuing into 2024. The same corporate families that appear in the Senate's abuse findings appear on the federal vendor list for children in immigration custody. In Texas alone, federal foster care program awards total roughly $3.59 billion across six programs and 297 awards — a funding stream that reimburses placement and treatment, not restraint reduction.

The Named Players and the Incentive Structure

The prescribing norms did not arise spontaneously. They were purchased.

The Texas Medication Algorithm Project (TMAP) was a state-authored prescribing guideline that steered Texas public patients toward newer, patented antipsychotics. Dr. Steven Shon, medical director of the Texas Department of Mental Health and Mental Retardation and a principal author, signed consulting agreements with Janssen Pharmaceuticals and was paid $47,587 while promoting TMAP to other states. The Texas health department received as much as $6 million in outside contributions to implement TMAP, with Janssen among the largest contributors. The practical effect: Risperdal displaced haloperidol across Texas Medicaid at roughly forty times the cost, with comparable efficacy and a worse metabolic side-effect profile. Allen Jones, an investigator in Pennsylvania's Office of Inspector General who traced Janssen's payments as TMAP spread state to state, says he was blocked by superiors and fired when he continued.

The litigation confirmed the scheme. Texas settled with Johnson & Johnson and Janssen for $158 million in January 2012 — then the largest Medicaid fraud recovery in state history — over allegations the company falsely marketed Risperdal for off-label use and told physicians it was safe for children absent FDA approval. Texas and 36 other states reached a further $181 million settlement in August 2012. In November 2013, J&J paid $2.2 billion to resolve federal claims that included promoting Risperdal to children and people with intellectual disabilities.

The diagnostic category that justified the prescribing has its own paper trail. Senator Charles Grassley's 2008 investigation established that Harvard/Massachusetts General child psychiatrists Joseph Biederman, Thomas Spencer, and Timothy Wilens had failed to disclose a combined $4.2 million in pharmaceutical income. Biederman alone took $1.6 million in consulting and speaking fees between 2000 and 2007; in one instance he reported no Johnson & Johnson income for 2001 while J&J told Grassley it had paid him $58,169 that year. Biederman's work on pediatric bipolar disorder is associated with a roughly forty-fold increase in that diagnosis in children — and with the antipsychotic prescribing that followed it. Harvard and MGH found all three violated conflict-of-interest standards and sanctioned them in July 2011.

That was the pre-transparency era. CMS Open Payments now publishes industry payments to prescribers — and nothing in the child welfare system connects that database to the courtroom. Analyses of Open Payments have found that twelve of the twenty-two physicians who earned over $500,000 from pharmaceutical companies between 2009 and 2012 were psychiatrists, and identified individual psychiatrists collecting millions, overwhelmingly for speaking and travel. Broader research using Open Payments and Part D data across 667,278 physicians has repeatedly found payments associated with higher prescribing of the paid-for drug; one estimate puts the effect of a single detailing visit for quetiapine at roughly a 14 percent increase in prescribing over the following year.

Now hold that against the consent hearing. When a juvenile court judge signs an order authorizing an antipsychotic for a nine-year-old, no state requires anyone to tell the court whether the prescriber received money from the manufacturer. The data is public, free, searchable, and structurally excluded from the only proceeding where it would matter.

The Cases

Florida — Gabriel Myers. In April 2009, a seven-year-old in Florida foster care died by suicide. Four weeks earlier he had been prescribed Symbyax — fluoxetine plus olanzapine, carrying a black-box warning for suicidality in children — on top of Vyvanse. A DCF investigation found that neither his parents nor a judge had approved the medications, and that the drugs were not reflected in his case file. Florida's own workgroup found 15.2 percent of the state's foster children were on at least one psychotropic against roughly 5 percent of American children generally.

Texas — M.D. v. Abbott. Judge Janis Jack's court found Texas's use of psychotropic drugs on foster children "appalling," including a child under three on multiple psychotropics with no best-practice analysis ever conducted. Court monitors reported in March 2023 that 75 of 161 children's files reviewed showed prescriptions for four or more psychotropic medications. Jack tied the pattern directly to the economics, questioning the "massive amount of drugs that are given to these children just because these group homes really can't handle the children." In October 2024 the Fifth Circuit removed Jack from the thirteen-year-old case for "intemperate conduct," reassigned it to Chief Judge Randy Crane, and vacated the $100,000-per-day contempt fines. Rehearing was denied in February 2025; plaintiffs petitioned the Supreme Court in May 2025.

Missouri — M.B. v. Tidball. The first federal class action in the country focused solely on psychotropic drugging in foster care, filed in 2017 by Children's Rights, the National Center for Youth Law, Saint Louis University's legal clinics, and Morgan, Lewis & Bockius. Judge Nanette Laughrey granted final approval on December 5, 2019, covering as many as 13,000 children. The settlement created a Psychotropic Medication Advisory Committee, required informed consent and assent before new prescriptions, mandated secondary review by a child psychiatrist for specified prescriptions, guaranteed an independent second opinion when an outlier prescription is flagged, and installed a third-party validator. PMAC subsequently published the first excessive-dosage guidelines for foster children in the country.

Maine — Bryan C. v. Lambrew. Filed January 6, 2021 by Children's Rights, Bernstein Shur, and Maine Equal Justice; settled March 2024; approved by Judge Nancy Torresen on November 27, 2024. Maine must build a portable health records system, create informed consent procedures, and stand up a clinical review team evaluating prescriptions both prospectively and retrospectively.

Maryland. Filed January 2023 by Disability Rights Maryland, the ACLU of Maryland, Children's Rights, and Morgan Lewis. The complaint alleges as many as 34 percent of Maryland foster children receive psychotropic drugs, more than half of those on multiple drugs simultaneously, and — the number that defines the whole subject — nearly 75 percent of medicated children have no psychiatric diagnosis. Black children, over-represented in Maryland's foster population, face elevated risk. Judge Theodore Chuang stayed the case for mediation in March 2023.

Federal custody — Lucas R. v. Becerra. At Shiloh Residential Treatment Center in Manvel, Texas, staff admitted signing off on psychotropic medications for detained immigrant children in lieu of a parent, relative, or legal guardian. The named plaintiff, a 12-year-old from Guatemala, was transferred to Shiloh after refusing Zoloft that was causing him stomach pain. A court ordered children removed from the facility; the 2023 settlement requires ORR, for the first time, to follow an informed consent protocol, with Kathleen Noonan monitoring compliance and semiannual reports.

The Accountability Gap

The statute is not ambiguous. 42 U.S.C. § 622(b)(15), added by the Child and Family Services Improvement and Innovation Act of 2011 (P.L. 112-34), conditions a state's Title IV-B plan on describing its oversight of prescription medicines, "including protocols for the appropriate use and monitoring of psychotropic medication." HHS instructed states that protocols must address screening and evaluation, consent and assent, medication monitoring, availability of mental health expertise, and information sharing.

What HHS does not do is verify. Compliance is assessed through the narrative APSR and through Child and Family Services Reviews, which sample a small number of cases for general well-being. There is no dedicated audit, no penalty tied to psychotropic protocol failure, and no federal data element that would let anyone detect a state whose written protocol and actual prescribing have diverged. The result is precisely what the record shows: states file compliant paper and are found compliant.

Where independent auditors have actually looked, they have found the divergence every time.

• HHS OIG, 2015 (OEI-07-12-00320): reviewing second-generation antipsychotic claims for Medicaid children in the five highest-utilization states, found quality-of-care concerns in 67 percent of claims examined.
• HHS OIG, 2018 (OEI-07-15-00380): sampling 625 foster children from the five highest-utilization states, found one in three received no treatment planning or medication monitoring that their own state required — and that state requirements often did not incorporate professional practice guidelines. Documented cases included a 10-year-old with ADHD on an antipsychotic with no supporting medical documentation, and a 4-year-old on four psychotropics, two of them antipsychotics.
• HHS OIG, 2022–2023: separate audits concluded Indiana, California, Florida, and Michigan each "did not comply with requirements for documenting psychotropic and opioid medications prescribed for children in foster care" — the combination FDA has warned can cause slowed breathing and death.
• California State Auditor, Report 2015-131 (August 2016): foster youth prescribed above state dosage guidelines; counties failing to oversee prescribers; counties failing to obtain required court or parental approval; one-third of youth receiving no follow-up appointment within 30 days of starting a new psychotropic. Years later, multiple recommendations remained partially implemented or unaddressed.
• Senate Judiciary Subcommittee on Human Rights and the Law (Ossoff), April 2024: a 64-page report finding Georgia DFCS does not adequately monitor psychotropic administration and fails to follow its own protocols, alongside a state audit showing children received adequate mental and behavioral health care in only 13 percent of cases reviewed.
• GAO-24-107625 and the Senate Finance investigation: abuse, restraint, and inadequate treatment across residential facilities drawing federal dollars.

Six independent bodies. Fifteen years. One consistent finding.

Why It Matters, and What Would Actually Fix It

The children being medicated are the ones with the least capacity to object and the fewest people obligated to listen. Antipsychotics in children carry documented risks of rapid weight gain, type 2 diabetes, movement disorders, and prolactin elevation, and require metabolic monitoring that the OIG found routinely absent. The Maryland complaint's claim that nearly three-quarters of medicated foster children carry no psychiatric diagnosis describes something other than treatment. A child who is sedated is not being helped toward reunification, adoption, or independence; the young people quoted in "All I Did Was Sleep" describe losing years of school, relationships, and memory.

The fixes are known because several states already run them.

Independent clinical review before consent. Illinois has done this since July 1, 1992, contracting the University of Illinois Chicago's Clinical Services in Psychopharmacology program to independently review every psychotropic consent request for a child in DCFS custody — roughly 20,000 consultations a year by 2018, up from 2,527 in 1994. Missouri now requires secondary child-psychiatrist review of flagged prescriptions plus a guaranteed second opinion. Maine's settlement establishes prospective and retrospective clinical review. Texas's prior-authorization approach was found by Rutgers researchers to reduce antipsychotic prescribing without compromising care.

Restore the federal data. Reinstate the health-care tracking elements stripped from AFCARS in 2020: psychotropic drug counts, classes, duration, dose, and age at first prescription, reported by state and published. Nothing about the problem survives publication.

Audit § 622(b)(15) instead of reading it. Congress should condition Title IV-B funds on demonstrated adherence to filed protocols, verified by claims-data review, with a defined penalty. A filing requirement without an audit is a filing requirement without a law.

Put Open Payments in the courtroom. Any petition seeking authorization to medicate a child in state custody should attach the prescriber's Open Payments record for the manufacturer of the drug in question. The data already exists and costs nothing to retrieve.

Break the staffing substitution. Tie residential per-diem reimbursement to staffing ratios and restraint metrics, and require facilities to report chemical restraint separately from treatment. The Senate Finance recommendations point this direction; CMS and ACF have not implemented them.

There are signs of federal movement. ACF Assistant Secretary Alex Adams, confirmed October 7, 2025, has publicly identified overmedicated foster youth as a priority and announced a convening of state Medicaid and child welfare officials on the issue. That is a meeting, not an audit. The distinction is the entire history of this problem: for fifteen years the federal government has asked states to describe their protocols, and for fifteen years it has accepted the description as the fact.

---

Sources: GAO-12-201 · GAO-12-270T · GAO-14-651T · GAO-17-129 · GAO-24-107625 · HHS OIG OEI-07-12-00320 · HHS OIG OEI-07-15-00380 · OIG: Michigan · OIG: California · OIG: Florida · OIG: Indiana · 42 U.S.C. § 622 · CRS R43466 · ACF Information Memorandum IM-12-03 · Senate Finance, Warehouses of Neglect · Sen. Ossoff foster care investigation · NDRN, Desperation Without Dignity · The Imprint / MindSite News, "All I Did Was Sleep" · The Imprint, state policy documents · M.B. v. Tidball · Bryan C. v. Lambrew · Maryland class action · Lucas R. v. Becerra settlement · M.D. v. Abbott psychotropic findings · Fifth Circuit removes Judge Jack · California State Auditor 2015-131 · Gabriel Myers Work Group · Texas HHS psychotropic report FY2002–2024 · Texas $158M Risperdal settlement · J&J $2.2B settlement · Grassley/Harvard conflict findings · Open Payments prescribing association study · UIC Clinical Services in Psychopharmacology · AFCARS 2020 data removals · ACF on overmedicalization, 2026 · Federal award and grant-flow figures for the Devereux Foundation and Texas foster care programs from PMC CivicOps (USAspending / TAGGS).

---

A note on two figures I chose not to state flatly: a widely circulated claim that "92 percent" of Medicaid children on antipsychotics had none of the FDA-approved conditions appears in secondary coverage of the 2015 OIG report rather than in the report's headline findings, so I used the OIG's own 67 percent quality-of-care figure instead. The Texas HHS January 2026 report (FY2002–2024) is the most current state-level dataset available, but its PDF was not retrievable in this session — the Texas figures above come from court monitors and earlier Medicaid spending analyses. WebFetch was unavailable, so all sourcing here is from search results and PMC's own award databases; the Texas 2026 PDF and The Imprint's DocumentCloud state-policy set are the two highest-value documents to pull directly before publication.